270 related articles for article (PubMed ID: 23593455)
21. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B.
Loriot MA; Marcellin P; Bismuth E; Martinot-Peignoux M; Boyer N; Degott C; Erlinger S; Benhamou JP
Hepatology; 1992 Jan; 15(1):32-6. PubMed ID: 1727796
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and clinical management of HIV-HBV coinfected patients in a large AIDS Reference Center in Belgium.
Farid Y; Martin C; Delforge M; De Wit S
Acta Clin Belg; 2019 Dec; 74(6):424-429. PubMed ID: 30513065
[No Abstract] [Full Text] [Related]
23. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Sagoe KW; Agyei AA; Ziga F; Lartey M; Adiku TK; Seshi M; Arens MQ; Mingle JA
J Med Virol; 2012 Jan; 84(1):6-10. PubMed ID: 22095533
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
25. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort.
Zhu L; Zhai X; Wang Q; Jiang J; Peng H; Song C; Ge Z; Qian J; Zhou M; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhu F
J Viral Hepat; 2018 Dec; 25(12):1588-1598. PubMed ID: 30112835
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.
Hoffmann CJ; Charalambous S; Martin DJ; Innes C; Churchyard GJ; Chaisson RE; Grant AD; Fielding KL; Thio CL
Clin Infect Dis; 2008 Dec; 47(11):1479-85. PubMed ID: 18937580
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
[TBL] [Abstract][Full Text] [Related]
29. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.
Chen EQ; Wang TT; Bai L; Tao CM; Liang T; Liu C; Liao J; Tang H
Antivir Ther; 2013; 18(8):955-65. PubMed ID: 23639885
[TBL] [Abstract][Full Text] [Related]
30. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers.
Xun YH; Zang GQ; Guo JC; Yu XL; Liu H; Xiang J; Liu J; Shi JP
J Gastroenterol Hepatol; 2013 Nov; 28(11):1746-55. PubMed ID: 23800140
[TBL] [Abstract][Full Text] [Related]
31. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients.
Lee T; Núñez M
HIV Clin Trials; 2009; 10(3):153-9. PubMed ID: 19632954
[TBL] [Abstract][Full Text] [Related]
32. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
33. Characterization of treatment-naive HIV/HBV co-infected patients attending ART clinic of a tertiary healthcare centre in eastern India.
Saha D; Pal A; Biswas A; Panigrahi R; Sarkar N; Sarkar J; Pal M; Guha SK; Saha B; Chakrabarti S; Chakravarty R
PLoS One; 2013; 8(8):e73613. PubMed ID: 24023688
[TBL] [Abstract][Full Text] [Related]
34. HBeAg seroconversion in children infected during early childhood with hepatitis B virus.
Roushan MR; Bijani A; Ramzaninejad S; Roushan MH; Amiri MJ; Baiani M
J Clin Virol; 2012 Sep; 55(1):30-3. PubMed ID: 22727680
[TBL] [Abstract][Full Text] [Related]
35. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Khamduang W; Gaudy-Graffin C; Ngo-Giang-Huong N; Jourdain G; Moreau A; Luekamlung N; Halue G; Buranawanitchakorn Y; Kunkongkapan S; Buranabanjasatean S; Lallemant M; Sirirungsi W; Goudeau A;
PLoS One; 2012; 7(7):e42184. PubMed ID: 22860080
[TBL] [Abstract][Full Text] [Related]
36. Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates.
Zhang L; Gui XE; Wang B; Fan JY; Cao Q; Mullane K; Liang XL
BMC Infect Dis; 2016 Aug; 16(1):408. PubMed ID: 27515176
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
[TBL] [Abstract][Full Text] [Related]
38. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
[TBL] [Abstract][Full Text] [Related]
39. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX
Virol J; 2011 Sep; 8():444. PubMed ID: 21936898
[TBL] [Abstract][Full Text] [Related]
40. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.
Arendt E; Jaroszewicz J; Rockstroh J; Meyer-Olson D; Zacher BJ; Mederacke I; Manns MP; Wedemeyer H; Cornberg M; Wursthorn K
Viral Immunol; 2012 Dec; 25(6):442-7. PubMed ID: 23131018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
